View Document Preview and Link
Document Date: 2013-01-29 11:35:07 Open Document File Size: 24,64 KB Share Result on Facebook
City Philadelphia / San Francisco / / Company GeNO LLC / / Event Reorganization / FDA Phase / / Facility American College of Cardiology / American College of Cardiology’s Annual Scientific Session / / IndustryTerm treatment of a multitude of diseases / Hypertension therapies / larger / nasal cannula delivery systems / investigational product / compressed gas / nitric oxide delivery technologies / nitric oxide drug products / cartridge technology / pharmaceutical / combination products / stand-alone medical devices / nitric oxide delivery systems / Treatment of Right Ventricular (RV) Failure / inhaled nitric oxide treatment systems / nitric oxide gas / / MedicalCondition adult pulmonary arterial hypertension / Hypoxemia-induced Pulmonary Hypertension / Idiopathic Pulmonary Fibrosis / mean pulmonary arterial pressure / serious pulmonary and cardiac diseases / pulmonary vascular resistance / potential chronic treatment / expected selective acute pulmonary hemodynamic effects / Pulmonary Hypertension / hypoxemia induced pulmonary hypertension / diseases / hypoxic respiratory failure / acute and chronic Pulmonary Hypertension / persistent pulmonary hypertension / / MedicalTreatment cannula / / Organization FDA office of Combination Products / American College of Cardiology and American Thoracic Society Medical Meetings Waltham / Division of Cardiovascular and Renal Products / U.S. Food and Drug Administration / the American College / American College of Cardiology / / Person David Fine / Robert Roscigno / / Position Executive Vice President of Clinical Development / Chief Executive Officer / / Product MV-1000 nitric oxide delivery system / MV-1000 Inhaled Nitric Oxide / Nitric Oxide / GeNOsyl / MV-1000 / GeNOsyl™ MVG / GeNO / / ProvinceOrState Pennsylvania / California / / Technology nitric oxide delivery technologies / cartridge technology / / URL www.genollc.com / http / SocialTag